



## COMPANY OVERVIEW

Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.

## RECENT NEWS

### **MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan**

Jan 17 2019, 7:00 AM EST

### **MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDFN as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa**

Jan 15 2019, 7:00 AM EST

### **Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries**

Jan 11 2019, 5:00 AM EST

## STOCK OVERVIEW

Symbol	AMBS
Exchange	OTCPink
Shares OS	68,272,000
Market Cap	\$2.12M
Last Price	<b>\$0.031</b>
52-Week Range	<b>\$0.0151 - \$0.11</b>
Fiscal Year End	<b>December 31</b>

02/15/2019 02:21 PM  
EST

## INVESTOR RELATIONS

American Capital Ventures, Inc.  
Howard Gostfrand  
President  
T: 305-918-7000  
F: 305-468-6165  
[hg@amcapventures.com](mailto:hg@amcapventures.com)

## MANAGEMENT TEAM

**Gerald E. Commissiong**  
President & Chief Executive Officer

**Brian E. Harvey, MD, PhD**  
Chief Regulatory Advisor

**Elise Brownell, Ph.D.**  
Senior Vice President of Operations and  
Project Management

**John W. Commissiong, PhD**  
Chief Scientific Officer

**Paula Trzepacz, MD**  
Chief Medical Advisor to Elto Pharma

**Dr. Richard Kagan**  
Chief Medical Advisor to Cutanogen  
Corporation

**Michael T. Ropacki, PhD**  
Chief Medical Advisor - Alzheimer's Blood  
Diagnostic LymPro Test®

## AMARANTUS BIOSCIENCE HOLDINGS, INC.

45 Wall Street  
Suite 920  
New York, NY 10005  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.